

# Greater Manchester Joint Formulary & RAG/DNP list change log

21 June 2024

The list below includes changes made in the last 12 months. For information on older updates, contact [nuth.enquiries.gmmmg@nhs.net](mailto:nuth.enquiries.gmmmg@nhs.net)



Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
21/06/2024	1	1.2	Atropine eye drops for hypersalivation updated to green (following specialist advice)	Y	Y	8.1
21/06/2024	1	1.5.3	Link to azathioprine / 6MP SCP added	Y	Y	8.1
21/06/2024	2	2.12	Added links to GMMMG lipid pathway and inclisiran information for prescribers	n/a	Y	8.1
21/06/2024	2	2.5.4	Doxazosin 8mg immediate-release tablets added to DNP list, criterion 2. 1mg, 2mg, 4mg immediate release remain on formulary.	Y	Y	8.1
21/06/2024	4	4.2.2	Paliperidone 700mg & 1000mg LAI (6 month depots) added as amber. Link added to LAI shared care protocol	Y	Y	10.5
21/06/2024	4	4.2.3	Link added to lithium shared care protocol	Y	Y	10.5
21/06/2024	4	4.7.4.3	Lithium for cluster headache added, as per updated shared care protocol	Y	Y	10.5
21/06/2024	8	8.2.1	Link to azathioprine / 6MP SCP updated	Y	Y	10.6
21/06/2024	8	8.2.2	Added belumosudil as RED, as per NICE TA949	Y	Y	10.6
21/06/2024	8		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	10.6
21/06/2024	10	10.1.3	Link to azathioprine /6MP SCP added	Y	Y	8.1
21/06/2024	11	11.4.1	Link added to Prescribing information for primary care: Steroid Eye Drops for Ophthalmic Indications for adult patients	Y	Y	6.1
13/06/2024	4	4.7.4.2	Rimegepant RAG status updated to GREEN (following specialist advice) for prevention of migraine and GREEN for treatment of migraine	Y	Y	10.4
13/06/2024	4	4.9.3	Riluzole orodispersible film added as alternative to tablets	n/a	Y	10.4
13/06/2024	6	6.4.1.2	Benilexa and Levosert added as options for HRT, in line with GMMMG IUS comparison table	n/a	Y	10.1
13/06/2024	13	13.4	MHRA DSU added: Topical steroids: introduction of new labelling and a reminder of the possibility of severe side effects, including Topical Steroid Withdrawal Reactions	n/a	Y	7.1
13/06/2024	13	13.9	OT Csymbol added against coal tar shampoos	n/a	Y	7.1
13/06/2024	13	13.5.2	Amended "tar" to "coal tar" to improve searchability	n/a	Y	7.1
30/05/2024	3	3.3.2	MHRA DSU added: Montelukast: reminder of the risk of neuropsychiatric reactions	n/a	Y	9.1
30/05/2024	4	4.2.3	Safety information for valproate updated and streamlined to improve readability	n/a	Y	10.3
30/05/2024	5		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	8.0
30/05/2024	6	6.1.1.2	Cost charts for insulin pens updated	n/a	Y	10.0
30/05/2024	6	6.1.1.3	Cost charts for insulin needles updated	n/a	Y	10.0
30/05/2024	6		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	10.0
30/05/2024	9	6.4.2	MHRA DSU added: Finasteride: reminder of the risk psychiatric side effects and of sexual side effects (which may persist after discontinuation of treatment)	n/a	Y	10.0
30/05/2024	9	9.1.4	Hydroxycarbamide added as AMBER, to align with shared care protocol and RAG list	n/a	Y	7.1
30/05/2024	11	11.4.1	Link to GMMMG macular pathway updated to current wet AMD pathway	n/a	Y	6.0
30/05/2024	11		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	6.0
30/05/2024	12		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	6.0
30/05/2024	13		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	7.0
29/05/2024	1	1.5.2	Budesonide MR capsules (Kinpeygo) added to formulary as RED, with links to TA937	Y	Y	8.0
29/05/2024	2	2.5.5.1	Empagliflozin for CKD added as Green, as per NICE TA942	Y	Y	8.0
29/05/2024	4	4.1.1	Section updated to reflect preferred melatonin presentations for children	n/a	Y	10.2
29/05/2024	7	7.3.2.3	Link to levonorgestrel IUS table updated	n/a	Y	8.0

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
29/05/2024	7		Links to GM OTC Commissioning Policy updated to v3.0 throughout	Y	Y	8.0
29/05/2024	9	9.1	Hydroxycarbamide added as AMBER, to align with shared care protocol and RAG list	Y	Y	7.0
29/05/2024	9		Links to GM OTC Commissioning Policy updated to v3.0 throughout	Y	Y	7.0
29/05/2024	10	10.1.1	Diclofenac assigned third line status after Ibuprofen and naproxen.	n/a	Y	8.0
29/05/2024	10		Links to GM OTC Commissioning Policy updated to v3.0 throughout	Y	Y	8.0
29/05/2024	RAG	n/a	Sebelipase alfa added as RED, as per NICE HST30	Y	n/a	n/a
29/04/2024	2	2.12	Updated do not do recommendation on fibrates to align with NICE NG238 recommendation 1.12.2	n/a	Y	7.26
29/04/2024	2	various	Remove links to CG181 and replace with links to NG238.	n/a	Y	7.26
29/04/2024	7	7.3.2.3	Added Benilexa® One Handed IUS as an drug first line option alongside existing products on the formulary	n/a	Y	7.4
29/04/2024	13	13.5.3	Add indication of moderate to severe hidradenitis suppurativa to secukinumab with link to NICE TA935	n/a	Y	6.12
29/04/2024	RAG	n/a	Added Freestyle Libre 3 as RED to RAG list	Y	n/a	n/a
29/04/2024	RAG	n/a	Added link to SCP to RAG entry for amiodarone	Y	n/a	n/a
29/04/2024	RAG	n/a	Added link to SCP to RAG entry for dronedarone and changed from Green (specialist initiation) to Amber	Y	n/a	n/a
29/04/2024	RAG	n/a	Added velmanase alfa as RED and linked to HST29	Y	n/a	N/a
29/04/2024	RAG		Updated adalimumab and secukinumab entries to reflect NHSE commissioning for hidradenitis suppurativa	Y	n/a	n/a
11/04/2024	2	2.5.5.1	Add TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	Y	Y	7.25
11/04/2024	2	2.5.5.1	Add TA929: Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction	Y	Y	7.25
11/04/2024	4	4.10.2	Remove black triangle from varenicline	n/a	Y	10.1
11/04/2024	4	4.10.2	Remove black triangle from varenicline	n/a	Y	10.1
11/04/2024	4	4.10.2	Added cytisine for smoking cessation as green.	Y	Y	10.1
11/04/2024	7	7.4.2	Links to retired GM pathways deleted	n/a	Y	7.3
11/04/2024	7	7.4.2	Links to retired GM pathways deleted	n/a	Y	7.3
11/04/2024	7	7.4.5	Remove tadalafil 5mg OD from DNP list, specify 2.5mg still DNP	Y	Y	7.3
11/04/2024	7	7.4.5	Remove tadalafil 5mg OD from DNP list, specify 2.5mg still DNP	Y	Y	7.3
08/04/2024	3	3.1	MHRA DSU added: Pseudoephedrine: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS)	n/a	Y	9.0
08/04/2024	3	3.1.5, 3.2	Links to TA10 and TA131 removed	n/a	Y	9.0
08/04/2024	3	3.1.1, 3.2	Links to BTS/SIGN asthma guidance updated	n/a	Y	9.0
08/04/2024	3	3.4.1	Links to retired GM pathways deleted	n/a	Y	9.0
08/04/2024	3	3.4.1	Link to retired SPS guidance on triamcinolone for hay fever deleted	n/a	Y	9.0
08/04/2024	3		Links to GM OTC Commissioning Policy updated to v3.0 throughout	n/a	Y	9.0
08/04/2024	4	4.7.2	Codeine linctus DNP listing copied to chapter 4, for completeness	n/a	Y	10.0
08/04/2024	4		Links to GM OTC Commissioning Policy updated to v3.0 throughout	pending	Y	10.0
08/04/2024	RAG		Sompatropin entries updated to signpost that there is also a paediatric RAG list entry	Y	n/a	n/a
02/04/2024	RAG		Text removed from RAG list, scheme expired: "For the period 5th December 2023 until 31st March 2024, this commissioning statement is not applicable to the conditions listed here as they are included in a Minor Ailments Service. Details of the GM Minor Ailments Service may be found here."	Y	n/a	n/a
28/03/2024	4	4.7.3	Links added to GMMMG gabapentinoid resource pack	n/a	Y	9.26
28/03/2024	4	4.9.1	Foslevodopa with foscarbidopa added to formulary as RED as per NICE 934	Y	Y	9.26
28/03/2024	6	6.1.2.3	Links added to GMMMG tirzepatide guidance	Y	Y	9.29

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
28/03/2024	8	8.3.4.1	Links added to NICE CG164: familial breast cancer.	n/a	Y	12.8
19/03/2024	4	4.7.4.2	Rimegepant for treatment of migraine removed, pending approval of updates to other indications; to be published together.	Y	Y	9.25
19/03/2024	RAG		Text added to RAG list: "For the period 5th December 2023 until 31st March 2024, this commissioning statement is not applicable to the conditions listed here as they are included in a Minor Ailments Service. Details of the GM Minor Ailments Service may be found here."	Y	n/a	n/a
15/03/2024	1	1.5.3	Mirikizumab added as RED as per NICE TA925	Y	Y	7.12
15/03/2024	3	3.7	Acetylcysteine 600mg effervescent tablets added as GREEN, first choice mucolytic in COPD, not suitable for patients requiring low sodium diet	Y	Y	8.11
15/03/2024	3	3.7	Carbocisteine made alternative choice of mucolytic in COPD and assigned GREEN status	Y	Y	8.11
15/03/2024	4	4.7.4.2	Rimegepant for treatment of migraine added as GREEN	Y	Y	9.24
15/03/2024	6	6.1.2.3	Tirzepatide for type 2 diabetes added as GREEN, as per NICE TA924. With note that it is an alternative to GLP-1 mimetics, not to be used for weight management pending NICE TA in that indication	Y	Y	9.28
15/03/2024	6	6.2.2	Carbimazole 10mg and 15mg tablets added to DNP list, criterion 2	Y	Y	9.28
15/03/2024	6	6.4.1.2	Gepretix 100mg micronised progesterone added as an additional option alongside Utrogestan in women requiring progesterone for HRT	n/a	Y	9.28
15/03/2024	10	10.1.3	Tofacitinib for active AS added as RED, as per NICE TA920	n/a	Y	7.19
15/03/2024	10	10.1.3	Bimekizumab for active PsA added as RED, as per NICE TA916	n/a	Y	7.19
15/03/2024	10	10.1.3	Bimekizumab for axial spondyloarthritis added as RED as per NICE TA918	n/a	Y	7.19
07/03/2024	2	2.12	MHRA DSU added: Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors	n/a	Y	7.24
07/03/2024	2	2.12	Links to retired GM PCSK9 guidance deleted	n/a	Y	7.24
07/03/2024	4	4.2.1, 4.2.2, 4.2.3	MHRA DSU added: Aripiprazole (Abilify and generic brands): risk of pathological gambling	n/a	Y	9.23
07/03/2024	4	4.2.3, 4.8.1	MHRA DSU added: Valproate (Belvo, Convulex, Depakote, Dyazantil, Epilim, Epilim Chrono or Chronosphere, Episenta, Epival, and Syonell ▼): new safety and educational materials to support regulatory measures in men and women under 55 years of age	n/a	Y	9.23
07/03/2024	4	4.8.2	Links to GM Palliative Care Guidance removed; not currently available.	n/a	Y	9.23
07/03/2024	9	9.1.2	MHRA DSU added: Vitamin B12 (hydroxocobalamin, cyanocobalamin): advise patients with known cobalt allergy to be vigilant for sensitivity reactions	n/a	Y	6.9
07/03/2024	13	13.9	Baricitinib for alopecia areata added to DNP list, as per NICE TA926	Y	Y	6.11
07/03/2024	13		Links to retired GM dermatology pathways deleted	n/a	Y	6.11
26/01/2024	5	5.3	Tocilizumab added as RED for COVID-19, as per NICE TA878	Y	Y	7.8
26/01/2024	5	5.3	Casirivimab / imdevimab for COVID-19 removed from formulary & RAG following as per NICE TA878	n/a	Y	7.8
26/01/2024	6	6.1.1.2	Links to NICE Key Therapeutic Topics 12 & 20 deleted (KTTs retired by NICE).	n/a	Y	9.27
26/01/2024	6	6.3.2	Prednisolone 2.5mg & 5mg enteric coated tablets removed from DNP list	Y	Y	9.27
26/01/2024	RAG		Mavacamten added as RED, as per NICE TA 913	Y	n/a	n/a
14/01/2024	2	2.8	Edoxaban entry amended to reference to remove retired statement on GM DOAC statement	n/a	Y	7.23
22/12/2023	2	2.8.2	Apixaban made first choice DOAC in NVAF. No change in other indications	n/a	Y	7.22
22/12/2023	3	3.2	Fostair MDI replaced by Luforbec MDI	n/a	Y	8.10
22/12/2023	9		DNP entry for herbal medicines updated to include other natural products, in line with NHSE guidance on products not to be routinely prescribing in primary care	Y	Y	6.8
22/12/2023	12	12.1.2	Added link to NG233, otitis media with effusion in under 12s.	n/a	Y	5.1

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
22/12/2023	RAG		Cipaglucosidase alfa for Pompe disease added as RED, as per NICE TA912	Y	n/a	n/a
20/12/2023	10	10.1.3	Link to rituximab biosimilar statement deleted - statement no longer available.	n/a	Y	7.18
20/12/2023	10	10.1.4	Lesinurad deleted - no longer marketed	Y	Y	7.18
20/12/2023	10	10.2.2	Nusinersen formulation information corrected	n/a	Y	7.18
20/12/2023	10	10.3.2	Link to GMMMG neuropathic pain guideline updated	n/a	Y	7.18
18/12/2023	4	4.7.4.2	Rimegepant for preventing migraine added as GREEN (following specialist initiation) as per NICE TA906.	Y	Y	9.22
18/12/2023	4	4.7.4.2	Link added to GMMMG headache pathway	n/a	Y	9.22
18/12/2023	11	11.8.1	Sodium chloride 5% eye drops updated to GREEN (following specialist advice) for management of corneal oedema. Previously RED.	Y	Y	5.7
04/12/2023	2	2.12	Bempedoic acid updated to GREEN (from green following specialist advice). Links added to national lipid guidance and national statin intolerance pathway	Y	Y	7.21
04/12/2023	4	4.2.3, 4.8.1	MHRA DSU added: Valproate: dispense full packs of valproate-containing medicines	n/a	Y	9.21
04/12/2023	11	11.4.1	Betamethasone, dexamethasone, prednisolone and fluorometholone eye drops assigned GREEN (following specialist initiation) RAG status	Y	Y	5.6
04/12/2023	13	13.5.1	MHRA DSU added: Isotretinoin (Roaccutane ▼): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age	n/a	Y	6.10
04/12/2023	DNP		Semaglutide for obesity in 12-17 year olds, as per NICE TA910	Y	n/a	
15/11/2023	RAG		Tolvaptan entries corrected: incorrect entry for polycystic kidney disease deleted, information merged with other ICS-commissioned entry (SIADH not requiring chemotherapy)	Y	n/a	n/a
09/11/2023	1	1.5.3	Upadacitinib for previously treated moderately to severely active Crohn's disease added as RED, as per TA905	Y	Y	7.11
09/11/2023	2	2.12	MHRA DSU link added: Statins: very infrequent reports of myasthenia gravis (Sept 2023)	n/a	Y	7.20
09/11/2023	2	2.5.5.1	Dapagliflozin for chronic heart failure with preserved or mildly reduce ejection fraction added as GREEN (following specialist advice) as per NICE TA902	Y	Y	7.20
09/11/2023	3	3.4.2	Link added to omalizumab for chronic inducible urticarias commissioning statement (unlicensed)	n/a	Y	8.9
09/11/2023	13	13.5.3	Deucravactinib for moderate to severe plaque psoriasis added as per NICE TA907	Y	Y	6.9
01/11/2023	4	4.3.4	DNP entry for esketamine amended to add link to terminated NICE TA899 for major depressive disorder with imminent risk of suicide.	Y	Y	9.20
01/11/2023	5	5.3.3	Bulvertide added as RED, as per NICE TA896	Y	Y	7.7
01/11/2023	RAG		Link to NICE CG57 added to paediatric RAG list entry for emollient bath additives.	Y	n/a	n/a
30/10/2023	13	13.4	Error corrected - hydrocortisone 0.5% cream removed from DNP list, replaced with 0.5% ointment	Y	n/a	n/a
05/10/2023	1	1.5.3	Infliximab SC solution added as RED, for use as per other infliximab preparations	n/a	Y	7.10
05/10/2023	1	1.5.3	Vedolizumab SC solution added as RED, for use as per other vedolizumab preparations	n/a	Y	7.10
05/10/2023	1	1.5.3	Risankizumab for Crohn's disease added as RED, as per NICE TA888.	n/a	Y	7.10
05/10/2023	2	2.2, 2.4	Links to NICE CG127 removed and replaced with links to NG136, which superseded it.	n/a	Y	7.19
05/10/2023	6	6.1.2.3	Links to NG18 added alongside liraglutide, dulaglutide, empagliflozin	n/a	Y	9.26
05/10/2023	10	10.1.3	Infliximab SC solution added as RED, for use as per other infliximab preparations	n/a	Y	7.17
05/10/2023	13	13.4	Hydrocortisone 0.5% cream and 2.5% cream and ointment added to DNP list (criterion 2)	Y	Y	6.8
02/10/2023	8	8.2.2	Voclosporin added as RED, as per NICE TA882	Y	Y	12.7
02/10/2023	13	13.1	Difelikefalin added as RED, as per NICE TA890	Y	Y	6.7
28/09/2023	1	1.2	MHRA DSU link added: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia (July 2023)	n/a	Y	7.9

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
28/09/2023	1	1.5.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	7.9
28/09/2023	4	4.6	MHRA DSU link added: Hyoscine hydrobromide patches (Scopoderm 1.5mg Patch or Scopoderm TTS Patch): risk of anticholinergic side effects, including hyperthermia (July 2023)	n/a	Y	9.19
28/09/2023	4	4.2.3 & 4.8.1	MHRA DSU link added: Valproate: re-analysis of study on risks in children of men taking valproate (August 2023)	n/a	Y	9.19
28/09/2023	8	8	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	12.6
28/09/2023	10	10.1.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	7.16
28/09/2023	13	13.5.1 & 13.5.2 & 13.6.2	MHRA DSU link added: Oral retinoid medicines ▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women (July 2019)	n/a	Y	6.6
28/09/2023	13	13.5.3	MHRA DSU link added: Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions (August 2023)	n/a	Y	6.6
15/09/2023	6	6.1	Links added to GM guidance on managing GLP-1 shortages in T2DM	Y	Y	9.25
01/09/2023	2	2.5	Link added to new GMMMG hypertension pathway	n/a	Y	7.17
01/09/2023	3	3.4.2	Tezepelumab added as RED as per NICE TA880: Tezepelumab for treating severe asthma	Y	Y	8.8
01/09/2023	6	6.1.1.2	Statements on GLP-1 shortages added to the intermediate, long-acting and biphasic insulin sections, with links SPS advice on managing shortages	n/a	Y	9.24
01/09/2023	6	6.1.1.2	Toujeo updated to GREEN (was previously green specialist advice and GREY) to support management of GLP-1 shortages. Note added that this change is temporary, unless a successful application is received to make it permanent.	Y	Y	9.24
01/09/2023	6	6.1.1.2	Insulin cost charts updated	n/a	Y	9.24
01/09/2023	6	6.1.1.3	Insulin need cost chart updated	n/a	Y	9.24
01/09/2023	6	6.1.2.3	Statement on GLP-1 shortages added to the GLP-1 section, with cross-reference to insulin section and link to SPS advice	n/a	Y	9.24
01/09/2023	RAG		Fosfomycin for uncomplicated UTI changed to GREEN (was green specialist advice)	Y	n/a	n/a
23/08/2023	6	6.1.6	Dexcom ONE and Freestyle Libre 2 added to formulary	n/a	Y	9.23
07/08/2023	2	2.2.3	Finerenone added as GREEN (specialist advice) for CKD in type 2 diabetes, as per NICE TA877.	Y	Y	7.16
07/08/2023	4	4.5.1	Semaglutide injection added as RED, for prescribing by specialist weight management services only as per NICE TA875: Semaglutide for managing overweight and obesity	Y	Y	9.18
07/08/2023	4	4.7.2	Actimorph - add as GREEN and GREY, as an alternative to morphine sulfate tablets or oral solution 10mg/5ml	Y	Y	9.18
07/08/2023	4	4.7.4.2	Eptinezumab added as RED as per NICE TA871: Eptinezumab for preventing migraine	Y	Y	9.18
07/08/2023	6	6.3.2	Efmody added as Green (following specialist initiation) as an alternative option, only for patients not well controlled on standard release hydrocortisone and where specified criteria are met.	Y	Y	9.22
07/08/2023	RAG		Dapagliflozin added to paediatric RAG list for CKD 2-3 as RED	Y	n/a	n/a
28/07/2023	2	2.12	Typo corrected: bempedoic acid amended to Greep (specialist advice), aligning with CRG decision and RAG list	n/a	Y	7.15
28/07/2023	3	3.4.3	MHRA DSU link added: Adrenaline auto-injectors (AAIs): new guidance and resources for safe use, June 2023	n/a	Y	8.7
28/07/2023	4	4.1 & 4.7	MHRA DSU link added: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy, June 2023	n/a	Y	9.17
28/07/2023	4	4.8.1	Link added to NICE TA873: Cannabidiol for treating seizures caused by tuberous sclerosis complex	n/a	Y	9.17

Date	Chapter	Section	Change made	RAG/DNP list updated	Formulary updated	New chapter version no.
28/07/2023	5	5.1.7	Bezlotoxumab entry amended to remove link to retired HCD commissioning statement	Y	Y	7.6
28/07/2023	9	9.2.1.1	MHRA DSU link added: Calcium chloride, calcium gluconate: potential risk of underdosing with calcium gluconate in severe hyperkalaemia, June 2023	n/a	Y	6.7
28/07/2023	10	10.1.1	MHRA DSU link added: Non-steroidal anti-inflammatory drugs (NSAIDs): potential risks following prolonged use after 20 weeks of pregnancy, June 2023	n/a	Y	7.15
28/07/2023	RAG		Chloral hydrate and cloral betaine added as RED	Y	n/a	n/a
28/07/2023	RAG		Asfotase alfa added as RED as per NICE HST23: Asfotase alfa for treating paediatric-onset hypophosphatasia	Y	n/a	n/a
29/06/2023	2	2.9	Note added: "do not routinely offer aspirin for primary prevention of CVD", with link to CG181.	n/a	Y	7.14
29/06/2023	6	6.5.1	Somatrogon added as RED (pending shared care) as per NICE TA863	Y	Y	9.21
29/06/2023	10	10.1.3	NICE TA861, upadacitinib for non-radiographic axial spondyloarthritis, added as RED	Y	Y	7.14
29/06/2023	RAG		Vutisiran added as RED, as per NICE TA868	Y	n/a	n/a
29/06/2023	RAG		Ataluren added as RED, as per NST 22	Y	n/a	n/a